Loading blog post…
A complete guide to hair loss in women — the three most common types (female pattern hair loss/FPHL, telogen effluvium, alopecia areata) with clinical differentiation, the androgenetic mechanism behind FPHL, how to identify the cause through history and examination, evidence-based treatments (minoxidil topical and oral, spironolactone, low-level laser therapy, PRP injections), what blood tests to order, when to see a dermatologist or trichologist, and realistic treatment timelines and expectations.
· By MedSpot Editorial · 7 min read
Hair loss affects approximately 40% of women by age 50 — and unlike male pattern baldness, female hair loss is often underdiagnosed, undertreated, and carries significant psychological impact. Here is the complete evidence-based guide.
The most common cause of progressive hair thinning in women.
Pattern: Diffuse thinning over the crown and top of the scalp — the "Christmas tree" or central part widening pattern (Ludwig pattern). Unlike men, women rarely develop complete baldness; they maintain the frontal hairline but lose density centrally.
Mechanism: DHT (dihydrotestosterone) — converted from testosterone by 5-alpha-reductase in the follicle — binds androgen receptors in genetically susceptible follicles → follicular miniaturization:
Important: Women with FPHL often have normal circulating androgen levels — the follicular androgen sensitivity is the issue, not androgen excess. Blood tests for androgens are normal in most women with FPHL.
Who is at risk: Strong genetic component — if a mother or maternal grandmother had thinning hair, risk is significantly elevated. Onset is typically gradual, beginning in the 30s–40s, though it can begin in the 20s.
Pattern: Diffuse shedding across the entire scalp — not pattern-specific. Patient notices significantly more hair on the brush, shower drain, and pillow. The hair shed is telogen hairs (club hairs with a white root bulb).
Mechanism: A systemic stress causes a large proportion of anagen follicles to simultaneously shift to the telogen (resting) phase → 2–3 months later, the telogen hairs shed together as the new anagen hair pushes them out. The shedding appears 2–3 months after the triggering event.
Common triggers:
Prognosis: Acute telogen effluvium resolves spontaneously over 6–9 months once the trigger resolves. Chronic telogen effluvium (>6 months duration) requires identification and correction of the ongoing trigger.
Pattern: Sharply demarcated, smooth oval or round patches of hair loss — completely bald within the patch, with normal skin. May be single or multiple patches; rarely progresses to total scalp (alopecia totalis) or body (alopecia universalis) hair loss.
Mechanism: Autoimmune — cytotoxic T cells target the follicular bulge and bulb; the hair follicle loses its immune privilege (normally protected from immune attack). JAK1/JAK3 signaling drives the T-cell activity against follicles.
Markers: "Exclamation mark hairs" at the patch border (tapered at the base); nail pitting (20–50% of patients); family history of autoimmune thyroid disease.
Treatment: Topical/intralesional/oral corticosteroids; contact sensitizers (DPCP); baricitinib (Olumiant) and ritlecitinib (Litfulo) — JAK inhibitors FDA-approved for severe alopecia areata — represent the first targeted therapies for this condition.
| Feature | FPHL | Telogen Effluvium | Alopecia Areata |
|---|---|---|---|
| Pattern | Crown thinning, central part | Diffuse | Patchy, focal |
| Shedding | Gradual | Acute shedding | Hair shed from patches |
| Hairline | Preserved | Preserved | Preserved (in patches) |
| Onset | Years | Weeks–months | Weeks |
| Trigger | None (genetic) | Identifiable stress | Autoimmune |
| Pull test | Negative | Positive (>6 hairs) | Positive at patch margin |
For any significant hair loss, the following labs help exclude correctable systemic causes:
The only FDA-approved topical treatment for female pattern hair loss.
Mechanism: Minoxidil is a potassium channel opener — in the scalp, it increases blood flow to follicles and prolongs the anagen (growth) phase. The active form is minoxidil sulfate, converted by sulfotransferase enzymes in follicular cells. Individuals with low scalp sulfotransferase activity ("poor converters") respond minimally to topical minoxidil.
Forms for women:
Evidence: Olsen 2002 (RCT, 381 women): 5% minoxidil foam produced significantly greater improvement in hair density than 2% solution at 24 weeks. Gupta 2014 (meta-analysis): 2% topical minoxidil produced statistically significant hair count improvement vs. placebo across all included trials.
Timeline: Initial shedding increase in the first 2–6 weeks (telogen hair displacement by new anagen — a good sign). Visible improvement at 4–6 months; full response assessment at 12 months.
Low-dose oral minoxidil (0.25–1 mg/day for women) has emerged as an increasingly used option — avoids the scalp irritation and inconvenience of topical application, and delivers minoxidil systemically (bypasses the sulfotransferase conversion variability of topical).
Evidence: Ramos 2020 (retrospective, 100 women): Low-dose oral minoxidil 1 mg/day produced significant hair density improvement in FPHL and TE with good tolerability. Main side effects: mild hypertrichosis (fine body hair in some patients), fluid retention (rare at low doses), cardiac considerations in patients with underlying cardiovascular disease.
An aldosterone antagonist that also blocks androgen receptors — reduces DHT action at the follicle in androgen-sensitive FPHL.
Dose for hair loss: 100–200 mg/day (higher than doses used for acne). Requires blood pressure monitoring and potassium level checks (can cause hyperkalemia).
Evidence: Sinclair 2011 (prospective, 80 women with FPHL): 40% of patients on spironolactone 200 mg/day showed hair density improvement; 44% stabilization. Less robust RCT data than minoxidil; used off-label.
Contraindications: Pregnancy (teratogenic — potassium-sparing diuretics feminize male fetuses); requires reliable contraception.
5-alpha-reductase inhibitor — reduces DHT production. Well-established in male pattern baldness; used off-label in post-menopausal women.
Not used in premenopausal women without reliable contraception — teratogenic (feminization of male fetuses).
Evidence: Iorizzo 2006 (RCT, post-menopausal women): finasteride 1 mg/day produced modest improvement in hair density over 12 months in FPHL.
Autologous PRP injected into the scalp delivers concentrated growth factors (PDGF, VEGF, EGF, IGF-1) that stimulate follicular cells and prolong anagen.
Evidence: Cervantes 2020 (meta-analysis, 460 patients): PRP produced statistically significant improvements in hair count and thickness vs. baseline; most studies not placebo-controlled (difficult to blind intradermal injections). Considered an adjunct rather than standalone therapy.
Protocol: Monthly sessions for 3 months; maintenance every 4–6 months. Results plateau with ongoing maintenance.
FDA-cleared devices (laser combs, helmets) delivering 650 nm laser light to the scalp — the same photobiomodulation mechanism as red LED. Modest evidence for FPHL.
Jimenez 2014 (RCT): Laser comb 655 nm used 3× weekly for 26 weeks produced significant improvement in hair count vs. sham device. Modest effect size; requires ongoing use.
Looking for a hair loss consultation or PRP treatment? Browse med spa providers on MedSpot →